AI In Post -Market Surveillance Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global AI In Post -Market Surveillance Market Trends and Insights

Regulatory Mandates Intensify PMS/PV Digitization

Health authorities are strengthening surveillance regulations as accelerated approvals shift evidence generation downstream. The FDA’s October 2026 ICH E2B(R3) deadline eliminates free-text narratives, a change that previously accounted for 60% of case-processing time at several firms.^{[1]U.S. Food and Drug Administration, “ICH E2B(R3) Implementation,” FDA.gov} EMA’s electronic Periodic Safety Update Report requirement and the UK regulator’s 2024 medical-device guidance further highlight the non-compliance of manual workflows.^{[2]European Medicines Agency, “Real-World Evidence Guidance,” EMA.europa.eu} China’s revised Pharmacovigilance Inspection Guidelines have assigned Marketing Authorization Holder responsibilities, driving a 40% increase in cloud safety-platform purchases in 2025.^{[3]National Medical Products Administration, “Pharmacovigilance Inspection Guidelines,” NMPA.gov.cn} Collectively, these mandates establish a digital baseline that only AI-enabled systems can meet within statutory timelines.

Regulatory Acceptance of RWE Elevates Analytics Demand

Real-world evidence now directly influences label updates and benefit-risk assessments, encouraging companies to integrate AI into their analytics frameworks. The FDA Sentinel System utilized natural-language processing in 2025 to extract adverse events from 700 million patient records, reducing false-negative signal rates by 30%. EMA’s 2024 guidance permits sponsors to apply machine-learning models for confounding adjustments, provided they disclose validation methods.^{[4]International Council for Harmonisation, “ICH E2D(R1): Post-Approval Safety Data Management,” ICH.org} Sanofi’s Project ARTEMIS, which processes 700,000 cases annually, achieved 15% cost savings in 2025 and aims for 50% by 2027 by combining AI-driven case intake with real-world evidence analytics.

Migration to ICH E2B(R3) Standardizes Structured Safety Data

The E2B(R3) schema introduces 1,200 data fields and nested structures, enabling individual case safety reports to be fully machine-readable. The FDA’s October 2026 implementation follows EMA’s 2022 mandate, requiring sponsors to manage dual-format pipelines during a four-year transition period. Oracle’s Argus Safety 2026.1.01 release includes Smart Duplicate Search, which identifies cross-format duplicates with 94% precision, eliminating a manual bottleneck that previously affected up to 20% of incoming reports. The updated ICH E2D(R1) guideline has expanded the definition of reportable sources to include digital-health applications, increasing data inflows that AI systems must process.^{[5]International Society for Pharmaceutical Engineering, “ISPE GAMP AI Guide for Life Sciences,” ISPE.org}

Cloud-First PV/PMS Architectures Reduce TCO and Speed Rollouts

SaaS delivery is replacing on-premises systems as safety teams prioritize faster refresh cycles and reduced total cost of ownership. Veeva Vault Safety 26R1 introduced Case Intake Agent, reducing average processing time from 45 minutes to 8 minutes. EVERSANA’s ORCHESTRATE PV lowers lifecycle costs by 40% by eliminating server provisioning and patch management tasks, which traditionally consume one-third of pharmacovigilance IT budgets. Multinational companies, such as MSD, decommissioned 10 legacy databases after transitioning to Veeva’s unified global instance, reducing reconciliation efforts for 15% of cases.

AI Models Face GxP Validation and Explainability Challenges

The ISPE GAMP AI guide, a comprehensive 290-page document, expands traditional computer-system validation to include model training, drift monitoring, and interpretability. This development increases entry barriers for smaller biotech firms. The FDA's "Good AI Practice" framework, set to be implemented in January 2026, requires sensitivity analyses and external validation for high-stakes predictions, potentially delaying deployment timelines by several months. Additionally, CIOMS guidance mandates human review of every AI-generated safety signal before submission, limiting automation to approximately 70% of the workflow for end-to-end straight-through processing.

Interoperability Challenges and E2B(R3) Readiness Delays

A four-year gap between EMA and FDA mandates requires sponsors to manage dual pipelines, significantly increasing IT complexity. Despite the availability of translation tools, a 2025 survey indicated that 40% of firms faced quality issues when converting legacy cases, particularly with nested device-problem hierarchies. Moreover, Japan’s J-DREAMS database does not support direct E2B(R3) uploads, necessitating manual reconciliation and adding up to five business days per case.

Segment Analysis

By Application: Case Processing Still Leads While Signal Detection Accelerates

In 2025, Adverse Event Reporting & Case Processing accounted for 34.18% of the AI-driven post-market surveillance revenue, representing the largest market share. This segment grew as companies efficiently converted unstructured data such as emails, call-center transcripts, and physician letters into structured E2B(R3) messages, meeting regulatory requirements. Meanwhile, Signal Detection & Risk Management is projected to grow at a strong 17.88% CAGR through 2031, reflecting a shift toward proactive risk management as routine case intake processes become automated. The market for signal analytics is expanding as organizations integrate natural-language models to analyze spontaneous reports, EHR extracts, and literature for early safety signals. For example, advancements in duplicate-case identification have significantly reduced per-case costs, enhancing operational efficiency.

By End User: Pharmaceutical Majors Dominate While Biotech Surges

In 2025, pharmaceutical companies represented 41.67% of the market, driven by large-scale consolidations that streamlined operations and reduced manual reconciliation efforts. At the same time, biotechnology firms are expected to grow at an 18.15% CAGR through 2031, the highest among end users. This growth is attributed to smaller biotech teams adopting enterprise-grade safety solutions without requiring extensive IT infrastructure. This trend is expanding the market's reach, particularly among emerging biopharma companies.

Medical device manufacturers face distinct regulatory requirements under the EU Medical Device and In-Vitro Diagnostic Regulations, including post-market clinical follow-up studies that feed data directly into EUDAMED. However, fragmented national registries complicate cross-border analytics, resulting in slower spending growth compared to pharmaceutical companies.

By Deployment Mode: Cloud Remains Predominant, Yet On-Premises Rebounds

In 2025, cloud installations accounted for 58.31% of deployments, driven by SaaS solutions that reduced upfront costs and accelerated multi-region launches. While cloud-based systems are expected to maintain a significant market share, on-premises solutions are projected to grow at a 17.36% CAGR through 2031. Regulatory requirements for localized storage of sensitive patient data are influencing architecture choices, leading to the adoption of hybrid models that combine secure data storage with efficient analytics. For instance, AI-driven innovations in cloud-native systems have significantly reduced processing times, while cloud solutions have eliminated resource-intensive tasks associated with on-premises systems, optimizing operational budgets.

Geography Analysis

In 2025, North America accounted for 43.18% of the revenue, driven by the FDA's ICH E2B(R3) deadline in October 2026 and the expansion of the Sentinel System to include 700 million patient records. The region benefits from the Emerging Drug Safety Technology Program, which allows sponsors to pre-clear innovative AI models. This approach reduces the challenges of retrospective validation and accelerates platform adoption. U.S. sponsors are increasingly implementing real-world evidence pipelines that integrate EHR data, claims, and patient-generated health data. This integration increases both the volume and complexity of safety signals, requiring AI-driven triage.

Asia-Pacific is projected to achieve the fastest global CAGR of 18.54% through 2031. China's updated Pharmacovigilance Inspection Guidelines and mandatory data sovereignty regulations resulted in a 40% increase in on-premises platform agreements in 2025. Japan's expansion of the MID-NET database to cover 23 million patients enables device manufacturers to conduct post-market follow-ups without the need for new patient recruitment. This development reduces evidence-generation timelines from 18 months to just 6 months. Similarly, Australia and South Korea are establishing interconnected claims-EHR networks, creating significant opportunities for vendors to incorporate country-specific localization features.

Europe secured approximately one-third of the 2025 revenue, driven by the 2022 E2B(R3) mandate that prompted rapid modernizations. Under the Medical Device Regulation, device manufacturers face stringent post-market clinical follow-up requirements, which in turn expand the market size for AI in post-market surveillance across Europe. However, fragmented national device registries and varying health-data governance standards continue to hinder data consolidation, fostering the adoption of federated-analytics solutions. While the Middle East & Africa and South America collectively represent less than 10% of the revenue, they are expected to grow as cloud-native platforms overcome local IT infrastructure limitations.